Drug discovery company in the field of cancer metabolism
Metabomed has raised €16M across 1 funding round from 5 investors, most recently a Series A round in Apr 2016. Based in Yavne, Israel; founded 2014; active in Healthtech. Data as of 7 Aug 2026.
Timing: dormant vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2016-04-01 | Series A | €16M |
| Arkin Holdings,Boehringer Ingelheim Venture Fund,MS Ventures,Pfizer,Pontifax Funds |
| View deal → |
